Mereo BioPharma (UK) Probability of Future Stock Price Finishing Under 3.52
| 0A9G Stock | 3.55 0.15 4.41% |
Mereo |
Mereo BioPharma Target Price Odds to finish below 3.52
The tendency of Mereo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to 3.52 or more in 90 days |
| 3.55 | 90 days | 3.52 | roughly 2.77 |
Based on a normal probability distribution, the odds of Mereo BioPharma to drop to 3.52 or more in 90 days from now is roughly 2.77 (This Mereo BioPharma Group probability density function shows the probability of Mereo Stock to fall within a particular range of prices over 90 days) . Probability of Mereo BioPharma Group price to stay between 3.52 and its current price of 3.55 at the end of the 90-day period is near 1 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 1.35 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Mereo BioPharma will likely underperform. Additionally Mereo BioPharma Group has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Mereo BioPharma Price Density |
| Price |
Predictive Modules for Mereo BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mereo BioPharma Group. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Mereo BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mereo BioPharma is not an exception. The market had few large corrections towards the Mereo BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mereo BioPharma Group, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mereo BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.58 | |
β | Beta against Dow Jones | 1.35 | |
σ | Overall volatility | 0.34 | |
Ir | Information ratio | -0.14 |
Mereo BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mereo BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mereo BioPharma Group can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mereo BioPharma generated a negative expected return over the last 90 days | |
| Mereo BioPharma has high historical volatility and very poor performance | |
| Mereo BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 1000 K. Net Loss for the year was (34.2 M) with profit before overhead, payroll, taxes, and interest of 936 K. | |
| Mereo BioPharma generates negative cash flow from operations | |
| About 68.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: MREO Other Long-Term Liabilities 1.61 Mil - GuruFocus.com |
Mereo BioPharma Technical Analysis
Mereo BioPharma's future price can be derived by breaking down and analyzing its technical indicators over time. Mereo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Mereo BioPharma Group. In general, you should focus on analyzing Mereo Stock price patterns and their correlations with different microeconomic environments and drivers.
Mereo BioPharma Predictive Forecast Models
Mereo BioPharma's time-series forecasting models is one of many Mereo BioPharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Mereo BioPharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Mereo BioPharma Group
Checking the ongoing alerts about Mereo BioPharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Mereo BioPharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Mereo BioPharma generated a negative expected return over the last 90 days | |
| Mereo BioPharma has high historical volatility and very poor performance | |
| Mereo BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 1000 K. Net Loss for the year was (34.2 M) with profit before overhead, payroll, taxes, and interest of 936 K. | |
| Mereo BioPharma generates negative cash flow from operations | |
| About 68.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: MREO Other Long-Term Liabilities 1.61 Mil - GuruFocus.com |
Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.